This report provides a comprehensive analysis of the global Quetiapine Fumarate Sustained Release Tablets market, projecting significant growth through 2032. The study examines key market dynamics, including product segmentation by dosage, application types across hospitals and clinics, and detailed regional insights spanning the Americas, APAC, Europe, and MEA. By evaluating competitive landscapes and strategic maneuvers of leading players like Teva and Dr. Reddy's, the report identifies emerging opportunities and essential trends shaping the industry's future trajectory.

Market Overview

Global Market Outlook

The global Quetiapine Fumarate Sustained Release Tablets market is projected to experience significant growth from 2025 through 2032, expanding at a steady compound annual growth rate over the forecast period.

Regional Market Projections

• United States: The market for Quetiapine Fumarate Sustained Release Tablets in the United States is estimated to increase from 2025 through 2032, maintaining a consistent growth rate.
• China: The market for Quetiapine Fumarate Sustained Release Tablets in China is estimated to see an upward trajectory from 2025 to 2032, growing at a sustained compound annual growth rate.
• Europe: The European market for Quetiapine Fumarate Sustained Release Tablets is estimated to expand from 2025 through 2032, showing continuous growth throughout the forecast period.

Report Scope and Methodology

LPI (LP Information) Research Scope

LPI (LP Information)'s newest research report, the “Quetiapine Fumarate Sustained Release Tablets Industry Forecast,” examines historical sales and reviews total global Quetiapine Fumarate Sustained Release Tablets sales in 2025. The report provides a comprehensive analysis by region and market sector of projected Quetiapine Fumarate Sustained Release Tablets sales for the period of 2026 through 2032. With sales broken down by region, market sector, and sub-sector, this report delivers a detailed analysis of the global Quetiapine Fumarate Sustained Release Tablets industry.

Insight Report Capabilities

This Insight Report provides a comprehensive analysis of the global Quetiapine Fumarate Sustained Release Tablets landscape, highlighting key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

The report also analyzes the strategies of leading global companies, focusing on their Quetiapine Fumarate Sustained Release Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints. This analysis is designed to provide a better understanding of these firms’ unique positions within an accelerating global market.

Market Drivers and Forecast Nuance

The report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Quetiapine Fumarate Sustained Release Tablets. It breaks down the forecast by type, application, geography, and market size to highlight emerging pockets of opportunity. Utilizing a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study offers a highly nuanced view of the current state and future trajectory of the global Quetiapine Fumarate Sustained Release Tablets industry.

Summary of Findings

This report presents a comprehensive overview, market shares, and growth opportunities of the Quetiapine Fumarate Sustained Release Tablets market categorized by product type, application, key players, and key regions and countries.

Market Segmentation

By Type

• 50mg
• 200mg
• 300mg
• 400mg

By Application

• Hospital
• Clinic
• Others

By Region

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Key Market Players

The global key Quetiapine Fumarate Sustained Release Tablets players include Luye Pharma Limited, PHARMATHEN INVESTMENTS GROUP LIMITED, Seroquel, Teva Pharmaceutical Industries, and Dr. Reddy's Laboratories, among others. In terms of revenue, the global two largest companies occupied a significant portion of the market share in 2025.

Company Profiles

The following companies have been profiled based on inputs gathered from primary experts and an analysis of their coverage, product portfolio, and market penetration:

• Luye Pharma Limited
• PHARMATHEN INVESTMENTS GROUP LIMITED
• Seroquel
• Teva Pharmaceutical Industries
• Dr. Reddy's Laboratories
• Sun Pharmaceutical Industries
• Mylan N.V.
• Torrent Pharmaceuticals
• Lupin Limited
• Sandoz

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Quetiapine Fumarate Sustained Release Tablets Market Size (2021-2032)

    • 2.1.2 Quetiapine Fumarate Sustained Release Tablets Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Quetiapine Fumarate Sustained Release Tablets by Country/Region (2021, 2025 & 2032)

  • 2.2 Quetiapine Fumarate Sustained Release Tablets Segment by Type

    • 2.2.1 50mg

    • 2.2.2 200mg

    • 2.2.3 300mg

    • 2.2.4 400mg

    • 2.2.5 Quetiapine Fumarate Sustained Release Tablets Market Size by Type

      • 2.2.5.1 Quetiapine Fumarate Sustained Release Tablets Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.5.2 Global Quetiapine Fumarate Sustained Release Tablets Market Size Market Share by Type (2021-2026)

  • 2.3 Quetiapine Fumarate Sustained Release Tablets Segment by Application

    • 2.3.1 Hospital

    • 2.3.2 Clinic

    • 2.3.3 Others

    • 2.3.4 Quetiapine Fumarate Sustained Release Tablets Market Size by Application

      • 2.3.4.1 Quetiapine Fumarate Sustained Release Tablets Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.3.4.2 Global Quetiapine Fumarate Sustained Release Tablets Market Size Market Share by Application (2021-2026)

• 3 Quetiapine Fumarate Sustained Release Tablets Market Size by Player

  • 3.1 Quetiapine Fumarate Sustained Release Tablets Market Size Market Share by Player

    • 3.1.1 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Player (2021-2026)

    • 3.1.2 Global Quetiapine Fumarate Sustained Release Tablets Revenue Market Share by Player (2021-2026)

  • 3.2 Global Quetiapine Fumarate Sustained Release Tablets Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Quetiapine Fumarate Sustained Release Tablets by Region

  • 4.1 Quetiapine Fumarate Sustained Release Tablets Market Size by Region (2021-2026)

  • 4.2 Global Quetiapine Fumarate Sustained Release Tablets Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Quetiapine Fumarate Sustained Release Tablets Market Size Growth (2021-2026)

  • 4.4 APAC Quetiapine Fumarate Sustained Release Tablets Market Size Growth (2021-2026)

  • 4.5 Europe Quetiapine Fumarate Sustained Release Tablets Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021-2026)

  • 5.2 Americas Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2021-2026)

  • 5.3 Americas Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Quetiapine Fumarate Sustained Release Tablets Market Size by Region (2021-2026)

  • 6.2 APAC Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2021-2026)

  • 6.3 APAC Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021-2026)

  • 7.2 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2021-2026)

  • 7.3 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Quetiapine Fumarate Sustained Release Tablets by Region (2021-2026)

  • 8.2 Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Quetiapine Fumarate Sustained Release Tablets Market Forecast

  • 10.1 Global Quetiapine Fumarate Sustained Release Tablets Forecast by Region (2027-2032)

    • 10.1.1 Global Quetiapine Fumarate Sustained Release Tablets Forecast by Region (2027-2032)

    • 10.1.2 Americas Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.1.3 APAC Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.1.4 Europe Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.1.5 Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Forecast

  • 10.2 Americas Quetiapine Fumarate Sustained Release Tablets Forecast by Country (2027-2032)

    • 10.2.1 United States Market Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.2.2 Canada Market Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.2.3 Mexico Market Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.2.4 Brazil Market Quetiapine Fumarate Sustained Release Tablets Forecast

  • 10.3 APAC Quetiapine Fumarate Sustained Release Tablets Forecast by Region (2027-2032)

    • 10.3.1 China Quetiapine Fumarate Sustained Release Tablets Market Forecast

    • 10.3.2 Japan Market Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.3.3 Korea Market Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.3.4 Southeast Asia Market Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.3.5 India Market Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.3.6 Australia Market Quetiapine Fumarate Sustained Release Tablets Forecast

  • 10.4 Europe Quetiapine Fumarate Sustained Release Tablets Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.4.2 France Market Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.4.3 UK Market Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.4.4 Italy Market Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.4.5 Russia Market Quetiapine Fumarate Sustained Release Tablets Forecast

  • 10.5 Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.5.2 South Africa Market Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.5.3 Israel Market Quetiapine Fumarate Sustained Release Tablets Forecast

    • 10.5.4 Turkey Market Quetiapine Fumarate Sustained Release Tablets Forecast

  • 10.6 Global Quetiapine Fumarate Sustained Release Tablets Forecast by Type (2027-2032)

  • 10.7 Global Quetiapine Fumarate Sustained Release Tablets Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Quetiapine Fumarate Sustained Release Tablets Forecast

• 11 Key Players Analysis

  • 11.1 Luye Pharma Limited

    • 11.1.1 Luye Pharma Limited Company Information

    • 11.1.2 Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Product Offered

    • 11.1.3 Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Luye Pharma Limited Main Business Overview

    • 11.1.5 Luye Pharma Limited Latest Developments

  • 11.2 PHARMATHEN INVESTMENTS GROUP LIMITED

    • 11.2.1 PHARMATHEN INVESTMENTS GROUP LIMITED Company Information

    • 11.2.2 PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Product Offered

    • 11.2.3 PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 PHARMATHEN INVESTMENTS GROUP LIMITED Main Business Overview

    • 11.2.5 PHARMATHEN INVESTMENTS GROUP LIMITED Latest Developments

  • 11.3 Seroquel

    • 11.3.1 Seroquel Company Information

    • 11.3.2 Seroquel Quetiapine Fumarate Sustained Release Tablets Product Offered

    • 11.3.3 Seroquel Quetiapine Fumarate Sustained Release Tablets Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Seroquel Main Business Overview

    • 11.3.5 Seroquel Latest Developments

  • 11.4 Teva Pharmaceutical Industries

    • 11.4.1 Teva Pharmaceutical Industries Company Information

    • 11.4.2 Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Offered

    • 11.4.3 Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 Teva Pharmaceutical Industries Main Business Overview

    • 11.4.5 Teva Pharmaceutical Industries Latest Developments

  • 11.5 Dr. Reddy's Laboratories

    • 11.5.1 Dr. Reddy's Laboratories Company Information

    • 11.5.2 Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Product Offered

    • 11.5.3 Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Dr. Reddy's Laboratories Main Business Overview

    • 11.5.5 Dr. Reddy's Laboratories Latest Developments

  • 11.6 Sun Pharmaceutical Industries

    • 11.6.1 Sun Pharmaceutical Industries Company Information

    • 11.6.2 Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Offered

    • 11.6.3 Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 Sun Pharmaceutical Industries Main Business Overview

    • 11.6.5 Sun Pharmaceutical Industries Latest Developments

  • 11.7 Mylan N.V.

    • 11.7.1 Mylan N.V. Company Information

    • 11.7.2 Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Product Offered

    • 11.7.3 Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 Mylan N.V. Main Business Overview

    • 11.7.5 Mylan N.V. Latest Developments

  • 11.8 Torrent Pharmaceuticals

    • 11.8.1 Torrent Pharmaceuticals Company Information

    • 11.8.2 Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Product Offered

    • 11.8.3 Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 Torrent Pharmaceuticals Main Business Overview

    • 11.8.5 Torrent Pharmaceuticals Latest Developments

  • 11.9 Lupin Limited

    • 11.9.1 Lupin Limited Company Information

    • 11.9.2 Lupin Limited Quetiapine Fumarate Sustained Release Tablets Product Offered

    • 11.9.3 Lupin Limited Quetiapine Fumarate Sustained Release Tablets Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 Lupin Limited Main Business Overview

    • 11.9.5 Lupin Limited Latest Developments

  • 11.10 Sandoz

    • 11.10.1 Sandoz Company Information

    • 11.10.2 Sandoz Quetiapine Fumarate Sustained Release Tablets Product Offered

    • 11.10.3 Sandoz Quetiapine Fumarate Sustained Release Tablets Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 Sandoz Main Business Overview

    • 11.10.5 Sandoz Latest Developments

• 12 Research Findings and Conclusion